

Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation with regard to its accuracy or completeness, and expressly disclaim any liability for any loss whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



杭州启明醫療器械股份有限公司
Venus Medtech (Hangzhou) Inc.

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2500)

VOLUNTARY ANNOUNCEMENT

**UNAUDITED OPERATING STATISTICS FOR THE PERIOD FROM
JANUARY 1, 2021 TO JUNE 30, 2021**

This announcement is made by Venus Medtech (Hangzhou) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and product development progress of the Group. The board of directors (the “**Board**”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the six months ended June 30, 2021, and the comparative figures as set out below.

For the period from January 1 to June 30:

	2021	2020	Change
	<i>RMB'million</i>	<i>RMB'million</i>	<i>%</i>
Total Revenue	<u>239.3</u>	<u>102.0</u>	<u>134.6</u>

The increase in total revenue was attributable to: (i) increased sales revenue of TAVR product, VenusA-Valve; (ii) rapid growth of second generation TAVR product, VenusA-Plus; (iii) market penetration of TriGUARD3 in overseas market.

The Company is still in the process of finalizing the interim results of the Group for the six months ended June 30, 2021. The operating statistics disclosed above is unaudited and based on preliminary internal information of the Group, which may be subject to change and may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such operating information. They shall not be taken as a measure or indication of the Group's current or future operating or financial performance nor shall they be taken as a representation by the Group of the corresponding figures as may be provided in due course in the Group's audited or unaudited consolidated financial statements. As such, the above statistics is provided for investors' reference only. Shareholders of the Company and potential investors are advised not to place any reliance on the information disclosed herein but to exercise due caution when dealing in the securities of the Company. When in doubt, shareholders of the Company and potential investors are advised to seek professional advice from professional or financial advisers.

By order of the Board
Venus Medtech (Hangzhou) Inc.
Min Frank Zeng
Chairman

Hangzhou, July 26, 2021

As at the date of this announcement, the executive Directors are Mr. Min Frank Zeng, Mr. Zhenjun Zi and Mr. Lim Hou-Sen (Lin Haosheng); the non-executive Director is Ms. Nisa Bernice Wing-Yu Leung; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Wan Yee Joseph Lau and Mr. Chi Wai Suen.